|
Market Closed -
Nasdaq
07:00:00 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 8.470 USD | -0.59% |
|
+10.72% | +8.59% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,164 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 31.79% | - | - |
| Enterprise Value (EV) 1 | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,282 | 2,056 | 1,746 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 38.97% | -9.92% | -15.06% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.67x | 12.5x | 10.9x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.62x | 32,577x | 5.95x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.7x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.05x | 2.94x | 2.61x |
| EV / Revenue | 13.5x | 7.9x | 4.99x | 4.58x | 1.88x | 3.21x | 2.79x | 2.1x |
| EV / EBITDA | -12x | -14.6x | -16.2x | -1,592x | 4.8x | -13.2x | 10.5x | 6.2x |
| EV / EBIT | -12x | -14.4x | -15.9x | -812x | 4.82x | -4.49x | 8.32x | 5.53x |
| EV / FCF | -14.7x | -13.1x | -17x | -38.9x | 4.76x | -101x | 8.01x | 4.53x |
| FCF Yield | -6.81% | -7.63% | -5.88% | -2.57% | 21% | -0.99% | 12.5% | 22.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.308 | 0.678 | 0.7786 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 710.1 | 736.4 | 830.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -173.5 | 195.7 | 281.8 |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 315.5 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -581.8 | 175.1 | 248.6 |
| Net Debt 1 | -368.3 | - | 426.7 | 507.7 | - | 117.9 | -108.5 | -418.2 |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 8.470 | 8.470 | 8.470 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 23/2/22 | 21/2/23 | 26/2/24 | 24/2/25 | 26/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.67x | 3.21x | -13.15x | -.--% | 2.16B | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -71.62x | 13.03x | -68.47x | -.--% | 24.7B | |
| Average | 15.24x | 25.53x | 5.07x | 0.31% | 39.65B | |
| Weighted average by Cap. | 21.50x | 26.21x | 11.10x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
